Vancouver-based Numinus Wellness has announced the development of proprietary methods for testing and screening psychedelic mushroom compounds.
“The testing we’ve developed and validated at Numinus Bioscience will facilitate the safety and efficacy testing of psychedelics for our products, our clients and strategic partners, and, ultimately, the industry,” says Sharan Sidhu , the company’s science officer and general manager.
“Working with regulators, we look forward to establishing tools to create a stronger foundation of analytical methods for psychedelic compounds and products,” Sidhu adds.
Earlier this year, Numinus partnered with Optimi Health, a mushroom brand focused on the health and wellness markets, on an information package that was sent to Health Canada. The package included the chemical constituents of an investigational product, genotype and formulation information, and procedures and processes to produce a consistent dosage from psilocybe mushrooms.
The company completed its first legal
Read full article on The Growth Op
